Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNASDAQ:KURANASDAQ:SBPHNASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.23-3.6%$7.32$5.90▼$34.11$527.73M2.211.37 million shs2.03 million shsKURAKura Oncology$5.68-2.4%$6.11$5.41▼$23.48$491.75M0.51.20 million shs880,510 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/ASVRASavara$2.29+2.2%$2.92$1.89▼$5.11$395.80M0.441.43 million shs2.12 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-3.60%+11.06%-24.84%-59.15%-78.67%KURAKura Oncology-2.41%+0.71%-13.41%-26.33%-72.25%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SVRASavara+2.23%-19.37%-28.44%-8.03%-44.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.6272 of 5 stars4.32.00.00.03.22.51.3KURAKura Oncology4.4486 of 5 stars4.52.00.04.73.30.80.6SBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara1.679 of 5 stars3.30.00.00.02.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.60Moderate Buy$20.92189.30% UpsideKURAKura Oncology 2.93Moderate Buy$24.50331.34% UpsideSBPHSpring Bank Pharmaceuticals 0.00N/AN/AN/ASVRASavara 2.67Moderate Buy$7.17212.95% UpsideCurrent Analyst Ratings BreakdownLatest SBPH, SVRA, KURA, and ARVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$6.00 ➝ $2.005/28/2025SVRASavaraEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetIn-Line ➝ In-Line$3.00 ➝ $2.005/28/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $8.005/28/2025SVRASavaraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.005/19/2025KURAKura OncologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.005/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.005/5/2025ARVNArvinasTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$21.00 ➝ $11.005/2/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$16.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$426.90M1.24N/AN/A$8.17 per share0.88KURAKura Oncology$67.99M7.23N/AN/A$5.35 per share1.06SBPHSpring Bank PharmaceuticalsN/AN/AN/AN/A$2.16 per shareN/ASVRASavaraN/AN/AN/AN/A$1.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%7/29/2025 (Estimated)KURAKura Oncology-$152.63M-$2.10N/AN/AN/AN/A-44.09%-39.57%8/14/2025 (Estimated)SBPHSpring Bank Pharmaceuticals-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/ASVRASavara-$54.70M-$0.48N/AN/AN/AN/A-58.89%-46.44%8/11/2025 (Estimated)Latest SBPH, SVRA, KURA, and ARVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SVRASavara-$0.12-$0.12N/A-$0.12N/AN/A5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million3/27/2025Q4 2024SVRASavara-$0.11-$0.13-$0.02-$0.13N/A$0.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.644.64KURAKura Oncology0.0211.4711.47SBPHSpring Bank PharmaceuticalsN/A5.115.11SVRASavara0.1317.7017.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%KURAKura OncologyN/ASBPHSpring Bank Pharmaceuticals17.17%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%KURAKura Oncology6.40%SBPHSpring Bank Pharmaceuticals12.70%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million65.18 millionOptionableKURAKura Oncology13086.58 million73.49 millionOptionableSBPHSpring Bank Pharmaceuticals3017.27 millionN/ANot OptionableSVRASavaraN/A172.84 million162.82 millionOptionableSBPH, SVRA, KURA, and ARVN HeadlinesRecent News About These CompaniesHC Wainwright Downgrades Savara (NASDAQ:SVRA) to NeutralMay 31 at 1:21 AM | americanbankingnews.comDid Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky InvestigatesMay 30 at 11:15 AM | accessnewswire.comSavara (NASDAQ:SVRA) Cut to Neutral at HC WainwrightMay 30 at 8:16 AM | marketbeat.comSavara's (SVRA) Buy Rating Reaffirmed at GuggenheimMay 30 at 2:17 AM | americanbankingnews.comSavara (NASDAQ:SVRA) Price Target Cut to $2.00 by Analysts at Evercore ISIMay 30 at 2:17 AM | americanbankingnews.comWells Fargo & Company Has Lowered Expectations for Savara (NASDAQ:SVRA) Stock PriceMay 30 at 2:17 AM | americanbankingnews.comHC Wainwright & Co. Downgrades Savara (SVRA)May 29 at 5:14 PM | msn.comEvercore ISI Lowers Savara (NASDAQ:SVRA) Price Target to $2.00May 29 at 12:27 PM | marketbeat.comSavara’s SWOT analysis: molbreevi’s potential drives stock outlookMay 29 at 11:51 AM | uk.investing.comSavara (NASDAQ:SVRA) Price Target Lowered to $8.00 at GuggenheimMay 29 at 10:47 AM | marketbeat.comWells Fargo & Company Issues Pessimistic Forecast for Savara (NASDAQ:SVRA) Stock PriceMay 29 at 9:56 AM | marketbeat.comLevi & Korsinsky Launches Fraud Investigation on Behalf of Savara Inc. (SVRA) ShareholdersMay 28 at 9:54 PM | markets.businessinsider.comSVRA ALERT: Levi & Korsinsky Investigates Savara Inc. on Behalf of Shareholders Who Lost MoneyMay 28 at 6:45 PM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAMay 28 at 6:10 PM | globenewswire.comLevi & Korsinsky Launches Fraud Investigation on Behalf of Savara Inc. (SVRA) ShareholdersMay 28 at 2:15 PM | accessnewswire.comFDA refuses to file Savara BLA for MolbreeviMay 28 at 1:10 PM | thepharmaletter.comFDA rejects Savara’s rare lung disease drug over limited manufacturing dataMay 28 at 8:08 AM | endpts.comManufacturing issues scupper Savara's lead drug filingMay 28 at 8:08 AM | pharmaphorum.comSavara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's InvestigationMay 28 at 6:00 AM | accessnewswire.comSavara Shares Slide After FDA Declines Drug ApplicationMay 28 at 2:59 AM | marketwatch.comFDA calls for additional manufacturing data in refusal letter for Savara's respiratory assetMay 28 at 2:59 AM | fiercepharma.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBPH, SVRA, KURA, and ARVN Company DescriptionsArvinas NASDAQ:ARVN$7.23 -0.27 (-3.60%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$7.24 +0.01 (+0.14%) As of 05/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Kura Oncology NASDAQ:KURA$5.68 -0.14 (-2.41%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$5.78 +0.10 (+1.67%) As of 05/30/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Spring Bank Pharmaceuticals NASDAQ:SBPHSpring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.Savara NASDAQ:SVRA$2.29 +0.05 (+2.23%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.29 0.00 (0.00%) As of 05/30/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
